The 30-second summary
- Every GLP-1 carries an FDA black-box warning about medullary thyroid carcinoma (MTC), based on rodent studies showing thyroid C-cell tumours.
- In humans, the signal so far is small and not clearly above background. Large post-marketing analyses have not found a clinical increase in MTC.
- You should not take a GLP-1 if you or a close family member have a history of MTC or MEN-2 syndrome. Otherwise, the routine answer is: be aware of the symptoms, mention any family history to your prescriber, and report neck lumps promptly.
What the warning says, in the actual words
From the Wegovy and Mounjaro prescribing information, in the boxed warning at the top of every label:
In rodents, semaglutide / tirzepatide causes thyroid C-cell tumors. It is unknown whether [the medication] causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, as the human relevance of [the drug]-induced rodent thyroid C-cell tumors has not been determined.
[The medication] is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
This is the same warning class that all GLP-1 medications carry. It is not specific to one brand.
Where the warning came from
In two-year rodent studies submitted to the FDA, both semaglutide and tirzepatide produced dose-dependent increases in thyroid C-cell adenomas and carcinomas. The mechanism is plausible: GLP-1 receptors are present on rodent thyroid C-cells, and chronic stimulation of those receptors can drive proliferation.
The catch is that human C-cells have very few GLP-1 receptors compared with rodents. The mechanism that drives the rodent tumours may not apply in humans. This is why the warning uses "unknown", not because the FDA is being lawyerly, but because the biology genuinely differs.
What the human data shows
Several large post-marketing analyses have looked for an MTC signal in people taking GLP-1 agonists:
- The French CNAM cohort study (Bezin et al., 2023): Followed 2.5 million people, with about 45,000 on GLP-1s. Reported a modest signal for thyroid cancer with use longer than one year. The strongest signal was for medullary thyroid carcinoma. Diabetes Care
- The U.S. FDA Adverse Event Reporting System (FAERS): Disproportionate reporting of MTC events with GLP-1s, but this is a hypothesis-generating system, not a confirming one, reporting bias is real and significant.
- Several Scandinavian, U.K. and U.S. EHR analyses: Generally have not found a clinically meaningful increase in MTC incidence in GLP-1 users. (Pasternak B et al., BMJ 2024.)
The honest summary: the signal exists but is small, inconsistent, and possibly confounded. Large randomised data is still missing because MTC is rare, it would take very large, very long studies to detect a true increase if one exists.
Who really should not take a GLP-1
The contraindication is clear and absolute for two groups:
- Personal history of medullary thyroid carcinoma.
- MEN-2 (Multiple Endocrine Neoplasia type 2), a hereditary syndrome that includes a very high lifetime risk of MTC.
A first-degree relative (parent, sibling, child) with MTC is generally also a contraindication or at minimum a strong relative contraindication. If you fall into either category, the conversation with your prescriber is short: pick another medication.
A history of non-medullary thyroid cancers (papillary, follicular, anaplastic) is not a contraindication. These are different cell types and different biology. They are separate conversations.
What to watch for
The symptoms of medullary thyroid carcinoma are not subtle, but they are often mistaken for other things:
- A lump in the neck, often hard, fixed, not painful
- Hoarseness that does not resolve
- Difficulty swallowing that progresses
- Persistent neck pain
Routine thyroid screening, by ultrasound or blood test (calcitonin), is not recommended for everyone starting a GLP-1. The American Thyroid Association does not recommend it, and the FDA does not require it. If a lump or persistent neck symptom appears, that is the trigger for evaluation.
What this means in practice
For the overwhelming majority of women on a GLP-1, the thyroid risk is theoretical, the rodent biology may not translate, and the human signal remains uncertain. The drug is widely used, including in people with longstanding type-2 diabetes, with no large clinical wave of MTC after a decade-plus of use.
For a small group with personal or family history of MTC or MEN-2, the drug is off the table.
What to tell your prescriber before starting
A two-sentence family history is enough for a thoughtful prescriber:
- "Has anyone in my family had thyroid cancer? Specifically medullary thyroid cancer or any genetic endocrine syndromes?"
- "If I notice a lump in my neck while on this medication, how should I get evaluated?"
Both questions should be answered before your first injection.
What Steady does with this
Steady includes the thyroid family-history question in onboarding, and gates the dose recommendation behind it. If a woman flags MTC or MEN-2 history, the app recommends a conversation with her prescriber before logging a first dose. We don't make the decision; we make sure the question isn't skipped.
Sources
- FDA Prescribing Information, Wegovy. Boxed warning. Label
- FDA Prescribing Information, Mounjaro. Boxed warning. Label
- Bezin J et al. GLP-1 receptor agonists and thyroid cancer. Diabetes Care 2023;46:384-90. Diabetes Care
- Pasternak B et al. GLP-1 receptor agonists and thyroid cancer, Scandinavian cohort. BMJ 2024. BMJ
Medical disclaimer: Thyroid-related symptoms or a family history of endocrine cancers belong with your prescriber, not the internet. See our full medical disclaimer.